title: Reduction in Tedizolid Plasma Exposure among End-Stage Renal Disease Patients Undergoing Dialysis Is Explained by Variations in Ideal Body Weight.
authors.affiliation: Merck Research Laboratories, Merck & Co, Inc., Kenilworth, New Jersey, USA shawn.flanagan@merck.com.
authors.forename: Shawn
authors.initials: S
authors.lastname: Flanagan
authors.affiliation: Merck Research Laboratories, Merck & Co, Inc., Kenilworth, New Jersey, USA.
authors.forename: Philippe
authors.initials: P
authors.lastname: Prokocimer
mesh_terms: D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000493:pharmacokinetics*; D001424:Bacterial Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D056865:Ideal Body Weight; D007676:Kidney Failure, Chronic / Q000097:blood*; D008297:Male; D023303:Oxazolidinones / Q000009:adverse effects / Q000493:pharmacokinetics*; D006435:Renal Dialysis; D013777:Tetrazoles / Q000009:adverse effects / Q000493:pharmacokinetics*
chemical_list: D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D013777:Tetrazoles; C546016:tedizolid